Neurotox Res:缺血性卒中患者尿酸的预测价值

2015-09-28 phylis 译 MedSci原创

心血管疾病或卒中患者中,血清尿酸(UA)的重要性和功能尚不清楚。研究人员旨在评估卒中患者的UA水平以及内源性UA与急性缺血性卒中(AIS)患者临床预后的相关性,尤其是性别和UA水平与AIS预后可能的关系。研究人员筛选了缺血性卒中48h内的患者303名,101名患者进行了溶栓治疗。入院后第二天清晨测量血清UA(μmol/L)。患者预后用发病后90天mRS评估。根据血清UA水平,将患者分为四组。应用二

心血管疾病或卒中患者中,血清尿酸(UA)的重要性和功能尚不清楚。研究人员旨在评估卒中患者的UA水平以及内源性UA与急性缺血性卒中(AIS)患者临床预后的相关性,尤其是性别和UA水平与AIS预后可能的关系。

研究人员筛选了缺血性卒中48h内的患者303名,其中101名患者进行了溶栓治疗。入院后第二天清晨测量血清UA(μmol/L)。患者预后用发病后90天mRS评估。根据血清UA水平,将患者分为四组。应用二元多变量Logistic回归模型评估功能预后和内源性UA的临床相关性。对性别和正常肾小球滤过率分亚组分析。

不良功能预后与高龄、房颤病史、或者基线NHISS分数较高相关。校正潜在的混杂因素后,高UA(>380 μmol/L)或低UA(≤250 μmol/L)不良预后发生可能性是基线组(316-380 μmol/L)的2-3倍(OR值分别:2.95,2.78; 95 % CI分别1.14-7.61, 1.02-7.58)。在溶栓组也得到相同的结果。高UA和低UA值发生不良预后的风险是基线组9-18倍(OR分别为 18.50, 9.66;95 % CI: 2.041-167.67,1.42-65.88)。男性患者,高UA发生不良预后的风险是基线值8倍(UA 值: 279-334 μmol/L; OR 6.10, 95 % CI 1.62-22.93)。然而,女性患者UA 271-337 μmol/L发生不良预后的风险是基线组的7倍(UA 值 >337 μmol/L, OR 7.06, 95 % CI 1.00-49.81)。

适当范围内血清UA与AIS良好预后相关,但是UA水平太高或太低都是有害的。男性与女性患者AIS预后与UA水平关系不同,这就强调研究脑血管危险因素时对性别进行分层。

原文出处:

Zhang X1, Huang ZC1, Lu TS2,et al. Prognostic Significance of Uric Acid Levels in Ischemic Stroke Patients.Neurotox Res. 2015 Sep 16.


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1892681, encodeId=e75d18926814d, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Oct 09 23:41:00 CST 2015, time=2015-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806032, encodeId=8b68180603264, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Oct 25 00:41:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720061, encodeId=8a181e20061d4, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Wed Jun 08 13:41:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010329, encodeId=b7712010329aa, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Thu Sep 08 08:41:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37838, encodeId=821e3e838ef, content=临床工作可挖掘的东西很多呀。, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=509b1654337, createdName=jasonb, createdTime=Wed Oct 07 11:47:00 CST 2015, time=2015-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626460, encodeId=b84c162646026, content=<a href='/topic/show?id=558b100221c7' target=_blank style='color:#2F92EE;'>#预测价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100221, encryptionId=558b100221c7, topicName=预测价值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5f621038683, createdName=changjitao2016, createdTime=Wed Sep 30 07:41:00 CST 2015, time=2015-09-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1892681, encodeId=e75d18926814d, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Oct 09 23:41:00 CST 2015, time=2015-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806032, encodeId=8b68180603264, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Oct 25 00:41:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720061, encodeId=8a181e20061d4, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Wed Jun 08 13:41:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010329, encodeId=b7712010329aa, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Thu Sep 08 08:41:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37838, encodeId=821e3e838ef, content=临床工作可挖掘的东西很多呀。, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=509b1654337, createdName=jasonb, createdTime=Wed Oct 07 11:47:00 CST 2015, time=2015-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626460, encodeId=b84c162646026, content=<a href='/topic/show?id=558b100221c7' target=_blank style='color:#2F92EE;'>#预测价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100221, encryptionId=558b100221c7, topicName=预测价值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5f621038683, createdName=changjitao2016, createdTime=Wed Sep 30 07:41:00 CST 2015, time=2015-09-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1892681, encodeId=e75d18926814d, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Oct 09 23:41:00 CST 2015, time=2015-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806032, encodeId=8b68180603264, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Oct 25 00:41:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720061, encodeId=8a181e20061d4, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Wed Jun 08 13:41:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010329, encodeId=b7712010329aa, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Thu Sep 08 08:41:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37838, encodeId=821e3e838ef, content=临床工作可挖掘的东西很多呀。, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=509b1654337, createdName=jasonb, createdTime=Wed Oct 07 11:47:00 CST 2015, time=2015-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626460, encodeId=b84c162646026, content=<a href='/topic/show?id=558b100221c7' target=_blank style='color:#2F92EE;'>#预测价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100221, encryptionId=558b100221c7, topicName=预测价值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5f621038683, createdName=changjitao2016, createdTime=Wed Sep 30 07:41:00 CST 2015, time=2015-09-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1892681, encodeId=e75d18926814d, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Oct 09 23:41:00 CST 2015, time=2015-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806032, encodeId=8b68180603264, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Oct 25 00:41:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720061, encodeId=8a181e20061d4, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Wed Jun 08 13:41:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010329, encodeId=b7712010329aa, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Thu Sep 08 08:41:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37838, encodeId=821e3e838ef, content=临床工作可挖掘的东西很多呀。, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=509b1654337, createdName=jasonb, createdTime=Wed Oct 07 11:47:00 CST 2015, time=2015-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626460, encodeId=b84c162646026, content=<a href='/topic/show?id=558b100221c7' target=_blank style='color:#2F92EE;'>#预测价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100221, encryptionId=558b100221c7, topicName=预测价值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5f621038683, createdName=changjitao2016, createdTime=Wed Sep 30 07:41:00 CST 2015, time=2015-09-30, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1892681, encodeId=e75d18926814d, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Oct 09 23:41:00 CST 2015, time=2015-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806032, encodeId=8b68180603264, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Oct 25 00:41:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720061, encodeId=8a181e20061d4, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Wed Jun 08 13:41:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010329, encodeId=b7712010329aa, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Thu Sep 08 08:41:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37838, encodeId=821e3e838ef, content=临床工作可挖掘的东西很多呀。, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=509b1654337, createdName=jasonb, createdTime=Wed Oct 07 11:47:00 CST 2015, time=2015-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626460, encodeId=b84c162646026, content=<a href='/topic/show?id=558b100221c7' target=_blank style='color:#2F92EE;'>#预测价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100221, encryptionId=558b100221c7, topicName=预测价值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5f621038683, createdName=changjitao2016, createdTime=Wed Sep 30 07:41:00 CST 2015, time=2015-09-30, status=1, ipAttribution=)]
    2015-10-07 jasonb

    临床工作可挖掘的东西很多呀。

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1892681, encodeId=e75d18926814d, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Oct 09 23:41:00 CST 2015, time=2015-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806032, encodeId=8b68180603264, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Oct 25 00:41:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720061, encodeId=8a181e20061d4, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Wed Jun 08 13:41:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010329, encodeId=b7712010329aa, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Thu Sep 08 08:41:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37838, encodeId=821e3e838ef, content=临床工作可挖掘的东西很多呀。, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=509b1654337, createdName=jasonb, createdTime=Wed Oct 07 11:47:00 CST 2015, time=2015-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626460, encodeId=b84c162646026, content=<a href='/topic/show?id=558b100221c7' target=_blank style='color:#2F92EE;'>#预测价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100221, encryptionId=558b100221c7, topicName=预测价值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5f621038683, createdName=changjitao2016, createdTime=Wed Sep 30 07:41:00 CST 2015, time=2015-09-30, status=1, ipAttribution=)]

相关资讯

Cerebrovasc Dis: 无症状性实质出血史患者,静脉溶栓后脑内出血的风险未增加

背景:NINDS试验显示静脉给予rtPA能够改善急性缺血性卒中的神经功能预后。排除了脑内出血(ICH)史的患者,可能是基于这类患者出血的风险增加。然而,是否应反对或支持给予先前存在ICH的患者静脉rtPA溶栓,尚不清楚。研究人员旨在通过一项回顾性基于医院单中心研究确定给予这种患者静脉rtPA溶栓的安全性。方法:研究人员总数了2006年1月到2014年4月间医院卒中中心接受静脉rtPA治疗的所有患者

PLoS One: 评估急性缺血性卒中患者非工作日时间急诊治疗

背景和目的:非工作日时间急性缺血性卒中患者的急诊处理的质量是有争议的。因此,研究人员旨在分析在非工作日时间入院的患者性能指标,治疗治疗以及临床预后。 方法:研究选取了2007年9月到2008年8月在中国国家卒中登记(CNSR)的缺血性卒中患者,共4493名。正常工作日指周一到周五上午8点到下午5点到达急诊部的患者。非工作日时间包括工作日时间剩余事件以及法定假期。运动多变量logistic回归模型分

PLoS One:急性缺血性卒中应用白蛋白的安全性分析

背景:先前研究显示白蛋白治疗缺血性卒中与心肺的不良事件相关,脑出血的发生率较低。研究人员在白蛋白与急性卒中的(ALIAS)第2部分多中心试验中旨在研究,应用白蛋白后神经系统和心肺不良事件的发生。方法:缺血性卒中的患者,年龄在18-83岁之间,基线NHISS ≥ 6,在卒中开始后5h内随机给予ALB治疗或生理盐水作为对照组治疗。神经系统不良事件包括症状性脑出血,偏侧颅骨肥大,神经功能恶化,神经细胞死

中国制定血管内治疗新指南的意义何在?

过去十年间,缺血性卒中的再灌注治疗取得了飞速发展。静脉溶栓治疗是迄今唯一被证明有效的治疗方案,但其受到治疗时间窗较窄(4.5h)、再通率低于50%且大血管闭塞对溶栓药物反应不佳的限制。血管内治疗可使这些问题迎刃而解,故国内外学者一直在探索对大血管闭塞患者进行血管内治疗,但研究过程并非一帆风顺。 早期3项多中心、前瞻性、随机对照试验(IMSⅢ、MR

Int J Stroke:24h动态血压对急性缺血性卒中对短期、中期、长期预后

背景:缺血性脑卒中急性期的血压水平与预后之间的关系仍存在争议。目的:这篇综述主要评估脑缺血急性期收缩压和舒张压对卒中预后的预测价值,应用mRS分数评估卒中预后、动态血压监测方法测量血压,并与入院随机测量的血压的预测价值相比。方法:我们搜索卒中24h内入院并且入院24h内进行动态血压监测的患者。我们选取随访结束时,选取血压与良好预后的研究和血压与不良预后的研究。然后对平均血压对预后的影响,进行荟萃分

Atherosclerosis: 高强度的他汀治疗改善急性缺血性卒中的预后

背景和目的:目前尚无不同强度的他汀类药物对缺血性卒中患者长期预后影响的研究。研究人员旨在评估这种影响。方法:有436名急性缺血性卒中的出院患者(39.2%男性,年龄78.6 ± 6.7岁)。应用等效剂量的阿托伐他汀进行他汀药物的治疗。出院后一年,应用mRS评估患者的功能状态。不良预后为mRS分数2-6分。记录患者缺血性卒中,心肌梗死以及死亡的发生。结果:与服用阿托伐他汀10 mg/天的患者相比,服